Topical melatonin and topical rosuvastatin were both effective in reducing the severity of mild-to-moderate plaque PsO.

Guselkumab is efficacious in patients with moderate-to-severe psoriasis and a history of cancer.

Apremilast is effective for the treatment of moderate-to-severe plaque psoriasis short-term in pediatric patients.

Plaque psoriasis patients with lower blood monocyte counts at baseline achieved early response when treated with secukinumab.

Guselkumab has shown improvements in skin clearance, scalp itch, and patient-report health-related QoL in skin of colour patients.

IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical AD compared to other biologics.

A lack of published psoriasis images complicates communication with patients, according to a study from the University of Gothenburg,...

Psoriasis patients with pruritis and related sleep distrubances showed a lower quality of life in all domains.